Literature DB >> 27648687

Rooted in risk: genetic predisposition for low-density lipoprotein cholesterol level associates with diminished low-density lipoprotein cholesterol response to statin treatment.

Roelof Aj Smit1,2, Iris Postmus2, Stella Trompet1,2, Michael R Barnes3,4, Helen Warren3,4, Benoit J Arsenault5, Daniel I Chasman6,7, L Adrienne Cupples8,9, Graham A Hitman10, Ronald M Krauss11, Xiaohui Li12, Bruce M Psaty13,14, Charles M Stein15,16, Jerome I Rotter12, J Wouter Jukema1,17,18.   

Abstract

AIMS: To utilize previously reported lead SNPs for low-density lipoprotein cholesterol (LDL-c) levels to find additional loci of importance to statin response, and examine whether genetic predisposition to LDL-c levels associates with differential statin response.
METHODS: We investigated effects on statin response of 59 LDL-c SNPs, by combining summary level statistics from the Global Lipids Genetics and Genomic Investigation of Statin Therapy consortia.
RESULTS: Lead SNPs for APOE, SORT1 and NPC1L1 were associated with a decreased LDL-c response to statin treatment, as was overall genetic predisposition for increased LDL-c levels as quantified with 59 SNPs, with a 5.4% smaller statin response per standard deviation increase in genetically raised LDL-c levels.
CONCLUSION: Genetic predisposition for increased LDL-c level may decrease efficacy of statin therapy.

Entities:  

Keywords:  MR–Egger; pharmacogenetics; statin therapy

Mesh:

Substances:

Year:  2016        PMID: 27648687      PMCID: PMC5558541          DOI: 10.2217/pgs-2016-0091

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  23 in total

1.  An introduction to instrumental variables for epidemiologists.

Authors:  S Greenland
Journal:  Int J Epidemiol       Date:  2000-08       Impact factor: 7.196

2.  Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment.

Authors:  Jason S Simon; Maha C Karnoub; David J Devlin; Maria G Arreaza; Ping Qiu; Stephanie A Monks; Michael E Severino; Paul Deutsch; Joanne Palmisano; Alan B Sachs; Marvin L Bayne; Andrew S Plump; Eric E Schadt
Journal:  Genomics       Date:  2005-11-16       Impact factor: 5.736

3.  Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men.

Authors:  André J Tremblay; Benoît Lamarche; Valéry Lemelin; Lizbeth Hoos; Suzanne Benjannet; Nabil G Seidah; Harry R Davis; Patrick Couture
Journal:  J Lipid Res       Date:  2010-12-01       Impact factor: 5.922

4.  The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1).

Authors:  Margarita Garcia-Calvo; JeanMarie Lisnock; Herbert G Bull; Brian E Hawes; Duane A Burnett; Matthew P Braun; James H Crona; Harry R Davis; Dennis C Dean; Patricia A Detmers; Michael P Graziano; Meredith Hughes; D Euan Macintyre; Anthony Ogawa; Kim A O'neill; Sai Prasad N Iyer; Diane E Shevell; Marsha M Smith; Yui S Tang; Amanda M Makarewicz; Feroze Ujjainwalla; Scott W Altmann; Kevin T Chapman; Nancy A Thornberry
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-31       Impact factor: 11.205

Review 5.  Comparative effects of lipid-lowering therapies.

Authors:  Michael H Davidson; Peter P Toth
Journal:  Prog Cardiovasc Dis       Date:  2004 Sep-Oct       Impact factor: 8.194

Review 6.  Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.

Authors:  Lin Jia; Jenna L Betters; Liqing Yu
Journal:  Annu Rev Physiol       Date:  2011       Impact factor: 19.318

7.  Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease.

Authors:  Yue Qi; Jing Liu; Changsheng Ma; Wei Wang; Xiaohui Liu; Miao Wang; Qiang Lv; Jiayi Sun; Jun Liu; Yan Li; Dong Zhao
Journal:  J Lipid Res       Date:  2013-08-20       Impact factor: 5.922

8.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors:  C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321

9.  Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins.

Authors:  Iris Postmus; Stella Trompet; Harshal A Deshmukh; Michael R Barnes; Xiaohui Li; Helen R Warren; Daniel I Chasman; Kaixin Zhou; Benoit J Arsenault; Louise A Donnelly; Kerri L Wiggins; Christy L Avery; Paula Griffin; QiPing Feng; Kent D Taylor; Guo Li; Daniel S Evans; Albert V Smith; Catherine E de Keyser; Andrew D Johnson; Anton J M de Craen; David J Stott; Brendan M Buckley; Ian Ford; Rudi G J Westendorp; P Eline Slagboom; Naveed Sattar; Patricia B Munroe; Peter Sever; Neil Poulter; Alice Stanton; Denis C Shields; Eoin O'Brien; Sue Shaw-Hawkins; Y-D Ida Chen; Deborah A Nickerson; Joshua D Smith; Marie Pierre Dubé; S Matthijs Boekholdt; G Kees Hovingh; John J P Kastelein; Paul M McKeigue; John Betteridge; Andrew Neil; Paul N Durrington; Alex Doney; Fiona Carr; Andrew Morris; Mark I McCarthy; Leif Groop; Emma Ahlqvist; Joshua C Bis; Kenneth Rice; Nicholas L Smith; Thomas Lumley; Eric A Whitsel; Til Stürmer; Eric Boerwinkle; Julius S Ngwa; Christopher J O'Donnell; Ramachandran S Vasan; Wei-Qi Wei; Russell A Wilke; Ching-Ti Liu; Fangui Sun; Xiuqing Guo; Susan R Heckbert; Wendy Post; Nona Sotoodehnia; Alice M Arnold; Jeanette M Stafford; Jingzhong Ding; David M Herrington; Stephen B Kritchevsky; Gudny Eiriksdottir; Leonore J Launer; Tamara B Harris; Audrey Y Chu; Franco Giulianini; Jean G MacFadyen; Bryan J Barratt; Fredrik Nyberg; Bruno H Stricker; André G Uitterlinden; Albert Hofman; Fernando Rivadeneira; Valur Emilsson; Oscar H Franco; Paul M Ridker; Vilmundur Gudnason; Yongmei Liu; Joshua C Denny; Christie M Ballantyne; Jerome I Rotter; L Adrienne Cupples; Bruce M Psaty; Colin N A Palmer; Jean-Claude Tardif; Helen M Colhoun; Graham Hitman; Ronald M Krauss; J Wouter Jukema; Mark J Caulfield
Journal:  Nat Commun       Date:  2014-10-28       Impact factor: 14.919

10.  Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators.

Authors:  Brandon L Pierce; Stephen Burgess
Journal:  Am J Epidemiol       Date:  2013-07-17       Impact factor: 4.897

View more
  2 in total

Review 1.  New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease.

Authors:  Julius L Katzmann; Ulrich Laufs
Journal:  Curr Cardiol Rep       Date:  2019-06-21       Impact factor: 2.931

2.  Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational Study.

Authors:  Cátia Santos-Ferreira; Rui Baptista; Manuel Oliveira-Santos; Regina Costa; José Pereira Moura; Lino Gonçalves
Journal:  J Lipids       Date:  2019-08-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.